The ASSET Study aims to further our understanding into factors that are associated with severe treatment-related toxicities in young people being treated for acute lymphoblastic leukaemia (ALL). The ASSET Study includes a Registry (ASSET Registry), a health-related quality of life sub-study and an education/health economics sub-study. This study has been reviewed and approved by the Hunter New England Human Research Ethics Committee Reference No: 2019/ETH00693
The registry study collects information on experiences of toxicity (more serious side effects of treatment) throughout the child's treatment. The quality of life sub-study collects information on the impact of treatment on children and families' quality of life, including the emotional and social wellbeing of families throughout the child's treatment and in the 3 years following the end of treatment. The education/health economic sub-study will help us understand the impact of disease and toxicity on children's development and education, and calculate costs involved in the diagnosis and management of these toxicities.
We hope to use the results of the ASSET study to improve treatment and support for children and families, and to optimise their well-being and quality of life in the future.
Want to learn more?
You can learn more about each part of the ASSET study and access additional resources through the buttons below:
The ASSET Registry Study
Education/ Health Economics Sub-Study
Health-Related Quality of Life (HRQoL) Sub-Study
The ASSET Study team
Our research publications
Our funding bodies, participating centres, collaborating partners, and recommended resources